FC
BMRN icon

Financial Consulate’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Consulate’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43K Hold
60
– – ﹤0.01% 924
2026
Q1 		$3.39K Hold
60
– – ﹤0.01% 869
2025
Q4 		$3.57K Hold
60
– – ﹤0.01% 798
2025
Q3 		$3.25K Buy
+60
New +$3.43K ﹤0.01% 727

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Financial Consulate's BMRN Position: Q2 2026 in Review

Financial Consulate held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 60 shares worth $3.43K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

Financial Consulate first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.57K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Financial Consulate held 60 shares of BioMarin Pharmaceuticals worth $3.43K as of Q2 2026.
  • Financial Consulate left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #924 holding.
  • Financial Consulate first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Financial Consulate's BioMarin Pharmaceuticals position peaked at $3.57K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.